Rubber Joint Contract for AstraZeneca Pharmaceuticals
Shanghai Songjiang provides rubber joint products for pharmaceutical factories. We supplied a batch of Shanghai Songjiang rubber joint products for AstraZeneca on September 23, 2014. Welcome to visit our factory.
AstraZeneca Pharmaceuticals Introduction:
AstraZeneca is an innovation-driven global integrated biopharmaceutical company. We focus on continuously exploring scientific frontiers and developing drugs that can change lives.
AstraZeneca is headquartered in London and has 57,500 employees globally. We have 22 production and supply bases in 16 countries, and our products are sold in more than 100 countries and regions worldwide. In 2014, our global sales reached 26.1 billion USD.
Recognizing the need to address future pharmaceutical demands, we actively explore unknown areas. AstraZeneca invests over $4.9 billion annually in research and development, utilizing strong technology and innovative techniques to continuously develop new drugs and ensure that we stay at the forefront of human disease research.
The Asia-Pacific market is a crucial part of AstraZeneca’s business growth and global layout, with China playing a pivotal role in the Asia-Pacific business development strategy. In 2014, AstraZeneca’s sales in China exceeded $2.2 billion.
As the future development hub for the Asia-Pacific region, including product research and development centers and market supply centers, AstraZeneca continues to increase its investment in China. Following the $290 million investment in the Wuxi supply base, AstraZeneca invested $300 million to establish its second supply base in Taizhou in 2012, which commenced commercial operations in October 2014.
The Wuxi supply base is located in Wuxi, Jiangsu Province. It covers an area of 96,000 square meters, with a building area of 58,000 square meters, officially commencing production in April 2001.
The Wuxi supply base possesses world-class production facilities, modern high-tech modular injection workshops, well-equipped laboratories, a safe and reliable elevated fully automated warehouse, and stable and complete public engineering facilities. The supply base has obtained GMP certification from China, the European Union, Australia, Brazil, Sudan, Argentina, and other countries. It produces cardiovascular, digestive, respiratory, central nervous system, oncology, and anti-infective products.
The Wuxi supply base adheres to AstraZeneca’s global unified quality standards and has gradually become one of the most important supply bases within AstraZeneca’s supply network, adopting lean and efficient advantages.
AstraZeneca attaches great importance to corporate social responsibility and is committed to making positive contributions to the economic and social development of Wuxi. AstraZeneca has repeatedly received the “Excellent Foreign Investment Enterprise Award” from the Wuxi Municipal Government and Wuxi New District Management Committee. From 2001 to 2014, it contributed a total of 7.4 billion RMB in taxes and received the “Tax Contribution Award” from the Wuxi Municipal Government and Wuxi New District multiple times. In addition, AstraZeneca has been recognized as the “National Pharmaceutical Industry Drug Quality Integrity Construction Demonstration Enterprise” by the China Association of Pharmaceutical Quality Management.
Every AstraZeneca employee upholds the company’s five core values in their work: “Science-based,” “Patient-centric,” “Achieving together,” “Ethical,” and “Pioneering spirit.” We constantly explore scientific frontiers and develop drugs that can change lives.
Related Product:【PTFE】DN150 Single Sphere Stainless Steel Flange Rubber Expansion Joint
